文献速递慢性肾脏病血液净化与透析水电解质与酸碱

磷酸盐管理的过去、现在与未来

Past, Present, and Future of Phosphate Management.
PubMed 文献 · Kidney Int Rep · 2022-02-01

透析患者心血管疾病占已知原因死亡的50%以上,血磷升高是慢性肾脏病(CKD)骨矿物质疾病和心血管疾病的重要非传统危险因素。磷结合剂是唯一获批治疗高磷血症的药物,但因其服用负担大、胃肠道副作用常见及加工食品和某些药物中「隐藏」磷酸盐的存在,多数透析患者未能持续达到目标血磷<5.5 mg/dl。靶向肠道磷吸收通路的新非结合剂疗法(EOS789作用于跨细胞途径,tenapanor靶向旁细胞途径)已开发。

要点

  • 透析患者心血管疾病占已知原因死亡的50%以上。
  • 磷结合剂因片剂大、味道差、每餐需多片及胃肠道副作用常见而负担重。
  • 多数透析患者未持续达到目标血磷<5.5 mg/dl,更少达到<4.5 mg/dl。

核心结论

  • 血磷浓度是改善CKD和终末期肾病(ESKD)患者健康的重要靶点,需要新方法改善磷酸盐管理和心血管健康。
  • 观察性证据已确立血磷浓度与死亡率等临床结局的强关联。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • 透析患者中,心血管疾病占已知原因死亡的50%以上。
  • 磷结合剂因片剂大、味道差、每餐和零食需多片及胃肠道副作用常见而成为负担,常导致治疗中断。
  • 加工食品和某些药物中「隐藏」磷酸盐使磷酸盐管理更具挑战性。
  • 多数透析患者未持续达到并维持目标血磷<5.5 mg/dl,更不用说更正常的<4.5 mg/dl。
  • EOS789作用于跨细胞途径,tenapanor靶向旁细胞途径。

关键数值与推荐

  • 透析患者目标血磷<5.5 mg/dl,更正常水平<4.5 mg/dl。
  • 心血管疾病占透析患者已知原因死亡的>50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular (CV) disease (CVD) accounts for >50% of deaths with known causes in patients on dialysis. Elevated serum phosphorus levels are an important nontraditional risk factor for bone mineral disease and CVD in patients with chronic kidney disease (CKD). Given that phosphorus concentrations drive other disorders associated with increased CV risk (e.g., endothelial dysfunction, vascular calcification, fibroblast growth factor-23, parathyroid hormone), phosphate is a logical target to improve CV health. Phosphate binders are the only pharmacologic treatment approved for hyperphosphatemia. Although their safety has improved since inception, the mechanism of action leads to characteristics that make ingestion difficult and unpleasant; large pill size, objectionable taste, and multiple pills required for each meal and snack make phosphate binders a burden. Side effects, especially those affecting the gastrointestinal (GI) system, are common with binders, often leading to treatment discontinuation. The presence of "hidden" phosphates in processed foods and certain medications makes phosphate management even more challenging. Owing to these significant issues, most patients on dialysis are not consistently achieving and maintaining target phosphorus concentrations of <5.5 mg/dl, let alone more normal levels of <4.5 mg/dl, indicating novel approaches to improve phosphate management and CV health are needed. Several new nonbinder therapies that target intestinal phosphate absorption pathways have been developed. These include EOS789, which acts on the transcellular pathway, and tenapanor, which targets the dominant paracellular pathway. As observational evidence has established a strong association between phosphorus concentration and clinical outcomes, such as mortality, phosphate is an important target for improving the health of patients with CKD and end-stage kidney disease (ESKD).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Doshi SM, Wish JB. Past, Present, and Future of Phosphate Management. Kidney Int Rep. 2022. PMID: 35497793. doi:10.1016/j.ekir.2022.01.1055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。